Use of early chemotherapy for hormone-sensitive prostate cancer: time for CHAARTED

CHAARTED was an ECOG-led phase III trial looking at early chemotherapy with the use of docetaxel in addition to androgen deprivation therapy (ADT) versus ADT alone in hormone-sensitive prostate cancer.

The positive results of the trial showing marked improvement in overall survival in those who received chemotherapy with ADT have revolutionized the treatment of metastatic castration-sensitive prostate cancer. In addition to overall survival, secondary endpoints such as time to castration resistance, PSA response were also significant for the patients who received early chemotherapy.

Asian journal of andrology. 2015 Oct 27 [Epub ahead of print]

Jeanny B Aragon-Ching

Clinical Program Director of Genitourinary Cancers, INOVA Dwight and Martha Schar Cancer Institute, 8505 Arlington Boulevard, Suite 100, Fairfax, VA, USA.

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe